title: Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis.
abstract: Infection with the Human T-cell Leukemia virus type I (HTLV-1) retrovirus results in a number of diverse pathologies, including the aggressive, fatal T-cell malignancy adult T-cell leukemia (ATL) and the chronic, progressive neurologic disorder termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Worldwide, it is estimated there are 15-20 million HTLV-1-infected individuals; although the majority of HTLV-1-infected individuals remain asymptomatic carriers (AC) during their lifetime, 2-5% of AC develops either ATL or HAM/TSP, but never both. Regardless of asymptomatic status or clinical outcome, HTLV-1 carriers are at high risk of opportunistic infection. The progression to pathological HTLV-1 disease is in part attributed to the failure of the innate and adaptive immune system to control virus spread. The innate immune response against retroviral infection requires recognition of viral pathogen-associated molecular patterns (PAMPs) through pattern-recognition receptors (PRR) dependent pathways, leading to the induction of host antiviral and inflammatory responses. Recent studies have begun to characterize the interplay between HTLV-1 infection and the innate immune response and have identified distinct gene expression profiles in patients with ATL or HAM/TSP--upregulation of growth regulatory pathways in ATL and constitutive activation of antiviral and inflammatory pathways in HAM/STP. In this review, we provide an overview of the replicative lifecycle of HTLV-1 and the distinct pathologies associated with HTLV-1 infection. We also explore the innate immune mechanisms that respond to HTLV-1 infection, the strategies used by HTLV-1 to subvert these defenses and their contribution to HTLV-1-associated diseases.
authors.affiliation: Molecular Oncology Group, Lady Davis Institute-Jewish General Hospital, and Department of Microbiology, McGill University, Montreal, Canada H3T 1E2.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Olière
authors.forename: Renée
authors.initials: R
authors.lastname: Douville
authors.forename: Alexandre
authors.initials: A
authors.lastname: Sze
authors.forename: S Mehdi
authors.initials: SM
authors.lastname: Belgnaoui
authors.forename: John
authors.initials: J
authors.lastname: Hiscott
mesh_terms: D000818:Animals; D015368:Human T-lymphotropic virus 1 / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000453:epidemiology / Q000276:immunology*; D009894:Opportunistic Infections / Q000453:epidemiology / Q000276:immunology; D015493:Paraparesis, Tropical Spastic / Q000453:epidemiology / Q000276:immunology*; D051192:Receptors, Pattern Recognition / Q000276:immunology
chemical_list: D051192:Receptors, Pattern Recognition